US4699788A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Angiogenic factor methods of extraction and method for producing angiogenesis
Assignee: Boston University
•
Filing: 1984-08-20
•
Granted: 1987-10-13
•
Expires: 2004-08-20
Abstract
Abstract A novel angiogenic composition obtained from the omentum is provided which acts as a potent and effective factor for blood perfusion enhancement and for the development of new blood vessels in an organized structural network in living tissues. The angiogenic composition is a lipid or lipids, essentially protein-free as extracted from the omentum using organic solvents. This composition can then be injected to target to a site where new blood vessel formation, or blood perfusion enhancement is required. This material can be used to heal various damaged tissues including bone and heart.
Inventors
- 👤 Nicholas Catsimpoolas
- 👤 Harry S. Goldsmith
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 18:02
CPC Classifications
A; A61; A61K; A61K38/00; A61K35/00; A61K35/12; A61K35/37; A61K31/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
63 words
A partially purified essentially non-protein angiogenic composition obtained from mammalian omenta by extraction with a solvent comprising at least one organic solvent and characterized by being a heterogeneous lipid containing fraction possessing systemic angiogenic or blood flow enhancement activity for mammalian tissues or organs wherein the systemic activity targets to a damaged, insufficient or abnormal vascular component of the mammalian tissue or organ.
Claim 2
Dependent Claim
63 words
A partially purified essentially non-protein angiogenic composition obtained from mammalian omenta by extraction with a solvent comprising at least one organic solvent and characterized by being a heterogeneous lipid containing fraction possessing systemic angiogenic or blood flow enhancement activity for mammalian tissues or organs wherein the systemic activity targets to a damaged, insufficient or abnormal vascular component of the mammalian tissue or organ.
Claim 3
Dependent Claim
10 words
The composition of claim 1 wherein the solvent is chloroform-methane.
Claim 4
Dependent Claim
16 words
The composition of claim 1 wherein angiogenic activity is determined according to the rabbit cornea test.
Claim 5
Dependent Claim
24 words
The composition of claim 1 wherein systemic targeting angiogenic or blood flow enhancement activity is determined according to a radioactive cat leg neovascularization test.
Claim 6
Dependent Claim
9 words
The composition comprising the active subfraction of claim 1.
Claim 7
Dependent Claim
37 words
The active subfraction of claim 5 in combination with the inactive fraction obtained when mammalian omenta is extracted with at least one organic solvent and wherein systemic targeting of angiogenic or blood flow enhancement activity is improved.
Claim 8
Dependent Claim
65 words
The angiogenically active composition of claims 1, 5, 6 for angiogenic or blood flow enhancement formulated for maintenance of mammalian organs or tissues in culture, or healing of, or acceleration of healing of: wounds, ulcers, muscle tissue, burns, bone fractures or breaks, myocardial infarcts, damage due to strokes, cerebral arterial insufficiency, coronary occlusions, restricted blood flow, damaged blood vessels, or diminished blood flow to extremities.
Claim 9
Dependent Claim
28 words
Method for neovascularization or blood flow enhancement of mammalian tissue which comprises treating a mammalian subject with vascular damage or insufficiency with the angiogenic composition of claim 1.
Claim 10
Dependent Claim
63 words
Method of claim 8 wherein the neovascularization or blood flow enhancement of mammalian tissues comprises maintenance of mammalian tissues or organs in culture, or healing of, or acceleration of healing of: wounds, ulcers, muscle tissue, burns, bone fractures or breaks, myocardial infarcts, damage due to strokes, cerebral arterial insufficiency, coronary occlusions, restricted blood flow, damaged blood vessels, or diminished blood flow to extremities.
Claim 11
Dependent Claim
70 words
Method for obtaining a composition active in systemic targeting angiogenesis or blood flow enhancement from mammalian omenta which comprises: (a) separating an omental homogenate into several layers which comprise a protein-containing layer and a lipid-enriched layer, and (b) extracting the omental lipid-enriched layer with a solvent comprising at least one organic solvent wherein there is obtained an essentially non-protein lipid fraction active in systemic targeting angiogenesis or blood flow enhancement.
Claim 12
Dependent Claim
70 words
Method for obtaining a composition active in systemic targeting angiogenesis or blood flow enhancement from mammalian omenta which comprises: (a) separating an omental homogenate into several layers which comprise a protein-containing layer and a lipid-enriched layer, and (b) extracting the omental lipid-enriched layer with a solvent comprising at least one organic solvent wherein there is obtained an essentially non-protein lipid fraction active in systemic targeting angiogenesis or blood flow enhancement.
References Cited (Backward Citations)
US4209587A
Cited
US4210718A
Cited
US4210719A
Cited
US4225670A
Cited
US4229532A
Cited
US4229531A
Cited
US4217412A
Cited
US4268629A
Cited
US4273871A
Cited
EP0038511A2
Cited
EP0095682A2
Cited
US4529590A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-10-12 | 1991-04-13 | 1991-10-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-10-12 | 1995-04-13 | 1995-10-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-10-12 | 1999-04-13 | 1999-10-13 | $7700.00 | Window Closed / Lapsed |